A Clinical Study on the First-line Treatment of Metastatic Pancreatic Cancer With TQB2916 Injection Combined With Gemcitabine Hydrochloride for Injection and Paclitaxel for Injection (Albumin-bound Type)

This study is testing a new drug combination as a first-line treatment for metastatic pancreatic cancer (cancer that has spread beyond the pancreas). The treatment includes a targeted drug called TQB2916, which is being combined with other agents. The goal is to see if this combination is effective and safe for patients who have not yet received any systemic treatment. **You may be eligible if...** - You are between 18 and 75 years old - You have been confirmed by biopsy to have pancreatic ductal adenocarcinoma (the most common type of pancreatic cancer) - Your cancer has measurable lesions on imaging - You have not received any prior cancer treatment for this disease - You are in good health (ECOG score 0–1) and your organs are functioning well **You may NOT be eligible if...** - You have had another cancer in the past 5 years (with some exceptions for early-stage cured cancers) - You have had major surgery within the past 28 days - You have had a serious bleeding event in the past 4 weeks - You had a stroke, blood clot, or pulmonary embolism in the past 6 months - You have active autoimmune disease or need ongoing immunosuppressive treatment - Your cancer has spread to the brain or spinal cord Talk to your doctor to see if this trial is right for you.